🔗 Share this article

Former Prime Minister Rishi Sunak has intensified his call for a focused testing initiative for prostate gland cancer.

During a recent discussion, he expressed being "persuaded of the urgency" of implementing such a initiative that would be affordable, feasible and "save innumerable lives".

These comments come as the British Screening Authority reconsiders its ruling from half a decade past against recommending regular testing.

Journalistic accounts suggest the authority may maintain its current stance.

Olympic Champion Contributes Support to Campaign

Olympic cycling champion Sir Chris Hoy, who has late-stage prostate cancer, advocates for younger men to be screened.

He recommends decreasing the minimum age for requesting a PSA laboratory test.

Currently, it is not standard practice to men without symptoms who are younger than fifty.

The PSA test is debated however. Levels can elevate for causes apart from cancer, such as inflammation, causing misleading readings.

Skeptics argue this can result in unnecessary treatment and side effects.

Focused Testing Proposal

The suggested screening programme would target men aged 45–69 with a family history of prostate gland cancer and black men, who face increased susceptibility.

This group encompasses around 1.3 million individuals individuals in the United Kingdom.

Organization calculations propose the system would cost twenty-five million pounds per year - or about £18 per individual - akin to intestinal and breast screening.

The projection envisions 20% of qualified individuals would be invited each year, with a nearly three-quarters uptake rate.

Diagnostic activity (scans and tissue samples) would need to rise by 23%, with only a moderate increase in NHS staffing, according to the study.

Clinical Community Response

Several medical experts are doubtful about the value of examination.

They argue there is still a possibility that patients will be intervened for the disease when it is not absolutely required and will then have to endure adverse outcomes such as urinary problems and erectile dysfunction.

One respected urological expert remarked that "The problem is we can often identify abnormalities that may not require to be managed and we end up causing harm...and my worry at the moment is that harm to benefit ratio requires refinement."

Individual Perspectives

Individual experiences are also shaping the discussion.

One example concerns a man in his mid-sixties who, after requesting a PSA test, was identified with the condition at the time of 59 and was advised it had spread to his pelvis.

He has since experienced chemotherapy, beam therapy and endocrine treatment but is not curable.

The man advocates examination for those who are genetically predisposed.

"That is very important to me because of my sons – they are in their late thirties and early forties – I want them tested as promptly. If I had been examined at 50 I am certain I would not be in the position I am currently," he said.

Next Steps

The Medical Screening Authority will have to weigh up the evidence and viewpoints.

Although the latest analysis suggests the consequences for personnel and capacity of a testing initiative would be manageable, others have contended that it would take scanning capacity otherwise allocated to patients being cared for for different health issues.

The current discussion highlights the complicated balance between timely diagnosis and potential overtreatment in prostate gland cancer treatment.